Objective: To compare angiotensin-converting enzyme (ACE) inhibitor use in patients with type 2 diabetes at 1 year and 3 years after guidelines were published. Study Design: Retrospective database ...

In a new study published in Science Signaling titled, “Restoration of striatal neuroprotective pathways by kinase inhibitor treatment of Parkinson’s linked-LRRK2 mutant mice,” researchers from ...

Glycogen phosphorylase (GP) is a pivotal enzyme responsible for the catabolism of glycogen into glucose, a process intricately linked to blood glucose regulation. In the context of type 2 diabetes, ...

Angiotensin-converting enzyme inhibitors (ACEi) are the leading cause of drug-induced angioedema in the USA, with an ...

3D structure of a melanoma cell derived by ion abrasion scanning electron microscopy [National Cancer Institute (NCI). Image created by Sriram Subramaniam, NCI] Researchers at Sanford Burnham Prebys ...

Objectives: To use a population management strategy to increase the proportion of patients with coronary artery disease (CAD) and diabetes receiving target-dose angiotensin-converting enzyme (ACE) ...

Molecular Tumor Board–Assisted Care in an Advanced Cancer Population: Results of a Phase II Clinical Trial The development of the selective RET inhibitors selpercatinib and pralsetinib has ...

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing innovative treatments for life-threatening immune and thrombotic conditions, today highlighted recent scientific ...

Please provide your email address to receive an email when new articles are posted on . There was a significant independent link between angiotensin-converting enzyme inhibitor use and all-cause ...

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...